Scott G Soltys1, Michael T Milano2, Jinyu Xue3, Wolfgang A Tomé4, Ellen Yorke5, Jason Sheehan6, George X Ding7, John P Kirkpatrick8, Lijun Ma9, Arjun Sahgal10, Timothy Solberg11, John Adler12, Jimm Grimm13, Issam El Naqa14. 1. Department of Radiation Oncology, Stanford University, Stanford, California. Electronic address: sgsoltys@stanford.edu. 2. Department of Radiation Oncology, University of Rochester, Rochester, New York. 3. Department of Radiation Oncology, NYU Langone Medical Center, New York, New York. 4. Department of Radiation Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York. 5. Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York. 6. Department of Neurologic Surgery, University of Virginia, Charlottesville, Virginia. 7. Department of Radiation Oncology, Vanderbilt University School of Medicine, Nashville, Tennessee. 8. Departments of Radiation Oncology and Neurosurgery, Duke Cancer Institute, Durham, North Carolina. 9. Department of Radiation Oncology, University of California, San Francisco, San Francisco, California. 10. Department of Radiation Oncology, Odette Cancer Center, Sunnybrook Health Sciences Center, University of Toronto, Toronto, ON, Canada. 11. Office of the Commissioner, US Food and Drug Administration, Silver Spring, Maryland. 12. Department of Neurosurgery, Stanford University, Stanford, California. 13. Department of Radiation Oncology, Geisinger Health System, Danville, Pennsylvania; Department of Medical Imaging and Radiation Sciences, Thomas Jefferson University, Philadelphia, Pennsylvania. 14. Machine Learning Department, Moffitt Cancer Center, Tampa, Florida.
Abstract
PURPOSE: We sought to investigate the tumor control probability (TCP) of vestibular schwannomas after single-fraction stereotactic radiosurgery (SRS) or hypofractionated SRS over 2 to 5 fractions (fSRS). METHODS AND MATERIALS: Studies (PubMed indexed from 1993-2017) were eligible for data extraction if they contained dosimetric details of SRS/fSRS correlated with local tumor control. The rate of tumor control at 5 years (or at 3 years if 5-year data were not available) were collated. Poisson modeling estimated the TCP per equivalent dose in 2 Gy per fraction (EQD2) and in 1, 3, and 5 fractions. RESULTS: Data were extracted from 35 publications containing a total of 5162 patients. TCP modeling was limited by the absence of analyzable data of <11 Gy in a single-fraction, variability in definition of "tumor control," and by lack of significant increase in TCP for doses >12 Gy. Using linear-quadratic-based dose conversion, the 3- to 5-year TCP was estimated at 95% at an EQD2 of 25 Gy, corresponding to 1-, 3-, and 5-fraction doses of 13.8 Gy, 19.2 Gy, and 21.5 Gy, respectively. Single-fraction doses of 10 Gy, 11 Gy, 12 Gy, and 13 Gy predicted a TCP of 85.0%, 88.4%, 91.2%, and 93.5%, respectively. For fSRS, 18 Gy in 3 fractions (EQD2 of 23.0 Gy) and 25 Gy in 5 fractions (EQD2 of 30.2 Gy) corresponded to TCP of 93.6% and 97.2%. Overall, the quality of dosimetric reporting was poor; recommended reporting guidelines are presented. CONCLUSIONS: With current typical SRS doses of 12 Gy in 1 fraction, 18 Gy in 3 fractions, and 25 Gy in 5 fractions, 3- to 5-year TCP exceeds 91%. To improve pooled data analyses to optimize treatment outcomes for patients with vestibular schwannoma, future reports of SRS should include complete dosimetric details with well-defined tumor control and toxicity endpoints.
PURPOSE: We sought to investigate the tumor control probability (TCP) of vestibular schwannomas after single-fraction stereotactic radiosurgery (SRS) or hypofractionated SRS over 2 to 5 fractions (fSRS). METHODS AND MATERIALS: Studies (PubMed indexed from 1993-2017) were eligible for data extraction if they contained dosimetric details of SRS/fSRS correlated with local tumor control. The rate of tumor control at 5 years (or at 3 years if 5-year data were not available) were collated. Poisson modeling estimated the TCP per equivalent dose in 2 Gy per fraction (EQD2) and in 1, 3, and 5 fractions. RESULTS: Data were extracted from 35 publications containing a total of 5162 patients. TCP modeling was limited by the absence of analyzable data of <11 Gy in a single-fraction, variability in definition of "tumor control," and by lack of significant increase in TCP for doses >12 Gy. Using linear-quadratic-based dose conversion, the 3- to 5-year TCP was estimated at 95% at an EQD2 of 25 Gy, corresponding to 1-, 3-, and 5-fraction doses of 13.8 Gy, 19.2 Gy, and 21.5 Gy, respectively. Single-fraction doses of 10 Gy, 11 Gy, 12 Gy, and 13 Gy predicted a TCP of 85.0%, 88.4%, 91.2%, and 93.5%, respectively. For fSRS, 18 Gy in 3 fractions (EQD2 of 23.0 Gy) and 25 Gy in 5 fractions (EQD2 of 30.2 Gy) corresponded to TCP of 93.6% and 97.2%. Overall, the quality of dosimetric reporting was poor; recommended reporting guidelines are presented. CONCLUSIONS: With current typical SRS doses of 12 Gy in 1 fraction, 18 Gy in 3 fractions, and 25 Gy in 5 fractions, 3- to 5-year TCP exceeds 91%. To improve pooled data analyses to optimize treatment outcomes for patients with vestibular schwannoma, future reports of SRS should include complete dosimetric details with well-defined tumor control and toxicity endpoints.
Authors: Jean Régis; Romain Carron; Michael C Park; Outouma Soumare; Christine Delsanti; Jean Marc Thomassin; Pierre-Hugues Roche Journal: J Neurosurg Date: 2010-12 Impact factor: 5.115
Authors: J G Rowe; M W R Radatz; L Walton; A Hampshire; S Seaman; A A Kemeny Journal: J Neurol Neurosurg Psychiatry Date: 2003-11 Impact factor: 10.154
Authors: Jennifer C Hall; Steven D Chang; Thomas J Wilson; Kristen N Ganjoo; Angus Toland; Hannes Vogel; Erqi L Pollom; Elham Rahimy Journal: Cureus Date: 2022-03-04
Authors: Maike Küchler; Rami A El Shafie; Sebastian Adeberg; Klaus Herfarth; Laila König; Kristin Lang; Juliane Hörner-Rieber; Peter Karl Plinkert; Wolfgang Wick; Felix Sahm; Simon David Sprengel; Jürgen Debus; Denise Bernhardt Journal: Cancers (Basel) Date: 2022-04-10 Impact factor: 6.575